| Drug Name | Dabrafenib |
|---|---|
| Other Drug Names | 2118436; DRB 436; GSK 2118436A; GSK-2118436; Tafinlar |
| Chemical Name | N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide |
| Formula | C23H20F3N5O2S2 |
| Mol. Wt. | 519.56 |
| CAS No. | 1195765-45-7 |
| UNII | QGP4HA4G1B |
| Target-based Actions | Raf B protein kinase inhibitor |
| ATC Codes | L01XE23 |
| Highest Status | 2013年批准上市 |
| Originator Company | GlaxoSmithKline |
| Structure |
 |
Extended Information